tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

RNAZ Stock Latest News

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Press ReleasesTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
18d ago
RNAZ
Transcode announces FDA clearance to initiate Phase 1/2 trial of TTX-MC138
PremiumThe Fly
Transcode announces FDA clearance to initiate Phase 1/2 trial of TTX-MC138
18d ago
RNAZ
TransCode Therapeutics Reports 2023 Results; Provides Business Update
PremiumPress Releases
TransCode Therapeutics Reports 2023 Results; Provides Business Update
1M ago
RNAZ
Transcode Therapeutics sees cash runway into late Q3/early 4Q24
PremiumThe Fly
Transcode Therapeutics sees cash runway into late Q3/early 4Q24
1M ago
RNAZ
Transcode Therapeutics reports 2023 EPS ($103.61) vs. ($1,082.79) last year
PremiumThe Fly
Transcode Therapeutics reports 2023 EPS ($103.61) vs. ($1,082.79) last year
1M ago
RNAZ
Transcode Therapeutics announces appointment of Vlock as CMO
PremiumThe FlyTranscode Therapeutics announces appointment of Vlock as CMO
1M ago
RNAZ
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
PremiumPress Releases
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
1M ago
RNAZ
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
PremiumPress Releases
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
2M ago
RNAZ
Transcode Therapeutics, Akribion report progress on CRISPR-derived tech
PremiumThe Fly
Transcode Therapeutics, Akribion report progress on CRISPR-derived tech
2M ago
RNAZ
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
PremiumPress Releases
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
2M ago
RNAZ
Transcode Therapeutics reports publication of U.S. patent application
PremiumThe Fly
Transcode Therapeutics reports publication of U.S. patent application
2M ago
RNAZ
TransCode Therapeutics Regains Nasdaq Compliance Status
PremiumCompany Announcements
TransCode Therapeutics Regains Nasdaq Compliance Status
3M ago
8K
RNAZ
Transcode regains compliance with Nasdaq stockholders’ equity requirement
PremiumThe FlyTranscode regains compliance with Nasdaq stockholders’ equity requirement
3M ago
RNAZ
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
PremiumPress Releases
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
3M ago
RNAZ
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
PremiumPress Releases
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
3M ago
RNAZ
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
PremiumPress Releases
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
3M ago
RNAZ
Transcode Therapeutics announces co-research agreement with Debiopharm
PremiumThe Fly
Transcode Therapeutics announces co-research agreement with Debiopharm
3M ago
RNAZ
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
PremiumPress Releases
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
3M ago
RNAZ
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
PremiumPress Releases
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
4M ago
RNAZ
Transcode Therapeutics Inc trading halted, news pending
PremiumThe FlyTranscode Therapeutics Inc trading halted, news pending
4M ago
RNAZ
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
PremiumPress Releases
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
4M ago
RNAZ
Transcode Therapeutics CEO Michael Dudley resigns
PremiumThe Fly
Transcode Therapeutics CEO Michael Dudley resigns
4M ago
RNAZ

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >